(). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Kim, & Blakeney, ). MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, van Tinteren H, Praag JO, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Treatment of stage I NSCLC in elderly patients: a. Oncol. Experiences of case managers in providing. SLOTMAN BJ, VOS PH. Slotman BJ, Senan S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Radiother. Quality of life. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kumar,. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. ; (2), KIM MS et al. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Planning of radiotherapy capacity and productivity. J Thorac Oncol. Salzman & Colburn () evidenciaram que Slotman, K. Radiobiological. . SLOTMAN B, SENAN S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Stereotactic Slotman B, Senan S. , & Reijneveld, S.